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An increased understanding of antitumor immunity is
necessary for improving cell-based immunother-
apies against human cancers. Here, we investigated
the roles of two immune system-expressed micro-
RNAs (miRNAs), miR-155 and miR-146a, in the regu-
lation of antitumor immune responses. Our results
indicate that miR-155 promotes and miR-146a
inhibits interferon g (IFNg) responses by T cells and
reduces solid tumor growth in vivo. Using a double-
knockout (DKO) mouse strain deficient in both miR-
155 and miR-146a, we have also identified an
epistatic relationship between these two miRNAs.
DKO mice had defective T cell responses and tumor
growth phenotypes similar to miR-155/ mice.
Further analysis of the T cell compartment revealed
that miR-155 modulates IFNg expression through
a mechanism involving repression of Ship1. Our
work reveals critical roles for miRNAs in the recip-
rocal regulation of CD4+ and CD8+ T cell-mediated
antitumor immunity and demonstrates the dominant
nature of miR-155 during its promotion of immune
responses.
INTRODUCTION
Combating solid tumors remains an enormous challenge for the
biomedical community. The need for improved therapies beyond
radiation and chemotherapy has become evident, and there is
growing interest in optimizing the use of immunotherapy as
a treatment option. Among the cell types that hold promising
therapeutic potential are T lymphocytes, including CD4+ inter-
feron g (IFNg)-expressing Th1 cells and cytotoxic CD8+ T cells,
which elicit tumor antigen-specific responses to direct the tumor
microenvironment in a manner that restricts or eliminates tumor
growth (Dougan and Dranoff, 2008; Dunn et al., 2004; Shiao
et al., 2011). However, there remain several aspects of antitumor
immunity that are unclear and appear to be governed by
complex regulatory systems that have limited this application
in the clinic thus far (Zitvogel et al., 2006). Therefore, an improvedCell Reunderstanding of the molecular networks that influence T
lymphocyte biology in the context of antitumor responses is
needed, and this has the potential to improve our ability to
manipulate this response in a manner that promotes tumor
rejection.
Mammalian miRNAs have recently emerged as important
regulators of immune cell development and function and repre-
sent a novel layer of control over cellular physiology (O’Connell
et al., 2010c). miRNAs are encoded by the genome and their
transcription is regulated in a manner similar to other inflamma-
tory protein coding genes, and this can involve such factors as
nuclear factor kB (NF-kB) and AP-1 (O’Connell et al., 2007; Ta-
ganov et al., 2006; Thai et al., 2007). Following their biogenesis,
miRNAs are loaded into the RNA-induced silencing complex
and guide this complex to the 30 UTRs of key target genes, re-
sulting in repressed expression (Filipowicz et al., 2008). In
recent years, specific miRNAs have been shown to dramatically
impact autoimmune and antimicrobial responses in mammals
through their regulation of inflammatory T cells (Lu et al.,
2009; O’Connell et al., 2010b; Rodriguez et al., 2007; Thai
et al., 2007).
One of the most prominent miRNAs linked to inflammation is
miR-155, which is upregulated in both myeloid and lymphoid
cells following their activation (Haasch et al., 2002; O’Connell
et al., 2007). In the T cell compartment, miR-155 regulates T
regulatory cell fitness through a mechanism involving Socs1
repression (Lu et al., 2009), while also being required for the
development of inflammatory Th17 cells during autoimmunity
driven by specific tissue antigens (Murugaiyan et al., 2011;
O’Connell et al., 2010b). miR-155 has been shown to be neces-
sary for effective vaccination against S. typhimurium and immu-
nity againstH. pylori (Oertli et al., 2011; Rodriguez et al., 2007). In
contrast to miR-155, miR-146a limits T cell activation and
promotes resolution of inflammatory responses. miR-146a/
mice develop spontaneous autoimmunity and cancer upon
aging, and this phenotype involves, among other things, hyper-
activation of T cells via derepression of its targets Irak1 and
Traf6 (Boldin et al., 2011; Yang et al., 2012; Zhao et al., 2011).
Stat1 has also been shown to be a functionally relevant target
ofmiR-146a/ in T regulatory cells (Lu et al., 2010). Thus, these
two miRNAs appear to have opposite impacts on inflammatory
responses carried out by T lymphocytes in the contexts of auto-
immunity and infection.ports 2, 1697–1709, December 27, 2012 ª2012 The Authors 1697
Figure 1. Enhanced Solid Tumor Growth in
miR-155/ Mice
(A) WT and miR-155/ mice were administered
2 3 106 EL4-luc cells subcutaneously in their rear
flanks and tumor growth was monitored over time
(n = 8). Tumor diameters and weights after 12 days
are shown.
(B) Tumors dissected from the mice in (A).
(C) Live animal imaging was performed to detect
tumor expression of luciferase.
(D) WT and miR-155/ mice were challenged
with 1 3 106 B16-F1 cells and their growth was
followed for 14 days. The dissected tumors from
the groups are shown.
(E and F) (E) Tumor weights from (D), or (F) from
mice given 5 3 105 B16-F10 melanoma cells for
19 days, are shown (n = 5–7).
(G andH) H&E-stained EL4-luc (G), or B16-F10 (H),
tumor sections from WT or miR-155/ mice
shown at the indicated magnifications.
* denotes a p value less than 0.05. Data are pre-
sented as ± SEM. In the 23 and 103 images, the
yellow arrows indicate necrosis. In the 403
picture, the yellow arrows indicate TILs and the red
arrows indicate macrophages.
See also Figure S1.To date, little is known about the roles of T cell-expressedmiR-
155 and miR-146a during antitumor immune responses. To
address this, we first tested the ability of miR-155 to mediate
antitumor immunity using multiple models of syngeneic solid
tumor growth in mice. We found that miR-155/ mice permit
enhanced growth of transplanted EL4-luc lymphoma and B16
melanoma cells compared to wild-type (WT) controls. This was
accompanied by a cell-intrinsic defect in IFNg-expressing
T cells in tumor-bearing mice. In contrast to miR-155/ mice,
miR-146a/ mice suppressed tumor growth compared to WT
controls, and this correlated with an elevated IFNg response.
Interestingly, mice deficient in both miR-155 and miR-146a, or
double-knockout (DKO) mice, had IFNg responses resembling
those observed in miR-155/ mice in vivo. Mechanistically,
we found that miR-155 regulates CD4+ T cell expression of
IFNg through a process involving repression of Ship1. These1698 Cell Reports 2, 1697–1709, December 27, 2012 ª2012 The Authorsfindings reveal that miRNAs are instru-
mental in directing CD4+ and CD8+
T cell-mediated antitumor responses,
and that miR-155 plays a dominant role
compared to miR-146a in the promotion
of IFNg-expressing T cell development
in this context.
RESULTS
Enhanced Growth of Syngeneic
Tumors inmiR-155/ Mice
To assess the impact of miR-155 on solid
tumor growth, we administered 2 3 106
syngeneic EL4-luc lymphoma cells
subcutaneously into WT or miR-155/mice and monitored tumor growth over a time course. Although
the tumor sizes were similar between the groups by day 9 post-
injection, substantial differences in tumor diameters and
weights were observed by day 12, with tumors growing much
larger in miR-155/ versus WT mice (Figures 1A and 1B).
Because the tumor cells express luciferase, we also found
that luciferase activity correlated with tumor size using Xenogen
whole animal imaging (Figures 1C and S1). Of note, we did not
observe a luciferase signal from locations other than the site
of tumor injection, suggesting that the tumor cells had not
metastasized. Next, we challenged both groups of mice with
two other types of syngeneic tumors, B16-F1 or B16-F10 mela-
noma cells, and once again observed increased tumor growth in
miR-155/ versus WT mice (Figures 1D, 1E, and 1F). Of note,
the differences in B16 tumor growth between the genotypes
were not as dramatic as those observed with the EL4-luc
tumors, which is probably a consequence of differences in
tumor immunogenicity.
Hematoxylin and eosin (H&E)-stained tumor tissue sections
revealed significant necrosis in tumors growing inWTmice, while
those growing inmiR-155/mice had few of these features (Fig-
ure 1G). Furthermore, we observed elevated numbers of tumor
infiltrating lymphocytes (TILs) in both EL4-luc and B16-F10
tumors growing in WT compared to miR-155/ hosts (Figures
1G and 1H). These observations indicate that miR-155/ mice
have a defect in limiting syngeneic tumor growth, and this corre-
lates with a reduced antitumor immune response.
Defective IFNg+CD4+ T Cell Development inmiR-155/
Tumor-Bearing Mice Occurring through a CD4+
T Cell-Intrinsic Mechanism
miR-155 is expressed predominately in the immune system
following cellular activation, and has been implicated in directing
antigen-specific responses and lineage skewing by lymphocytes
in vivo. Because IFNg-expressing T cells are instrumental in re-
pressing tumor growth (Ikeda et al., 2002; Jiang et al., 2011;
Maekawa et al., 1988; Muranski et al., 2011; Yim et al., 1999),
we assayed the amount of CD4+ IFNg-expressing T cells in WT
compared to miR-155/ tumor-bearing mice. In both the
spleens and lymph nodes of mice with EL4-luc tumors, a lack
of miR-155 led to significant reductions in both the percentage
and absolute number of IFNg-producing CD4+ T cells compared
to WT controls (Figures 2A, 2B, and S2). Of note, we only
observed significant differences in the total number of
IFNg+CD4+ splenic T cells in WT versus miR-155/ mice after
administration of the tumor (Figure 2C). Further demonstrating
a defective tumor immune response, we found that transfer of
total splenocytes from WT, but not miR-155/, tumor-bearing
mice protected naive WT mice from a primary tumor challenge
(Figure S3).
Next, we wanted to determine if this defective CD4+ T cell
response was due to cell-intrinsic or cell-extrinsic pathways
regulated by miR-155. To make this assessment, 4 3 106 naive
miR-155/ or WT CD45.2+ CD4+ T cells were transferred into
sublethally irradiated CD45.1+ WT recipients and 5 3 105 B16-
F10 tumor cells injected the next day. Consistent with miR-155
playing a CD4+ T cell-intrinsic role, the transferred CD45.2+
miR-155/ CD4+ T cells exhibited defective IFNg responses
compared to CD45.2+ WT CD4+ T cells in the tumors of
CD45.1+ WT recipient mice (Figures 2D and 2E). To corroborate
these findings, the reverse experiment was performed by adop-
tively transferring 4 3 106 naive CD45.1+ CD4+ WT T cells into
sublethally irradiated CD45.2+ WT or miR-155/ mice 1 day
before challenging thesemice with B16-F10 cells. Another group
of CD45.2+ miR-155/ mice received 4 3 106 naive CD45.2+
miR-155/ CD4+ T cells following irradiation, and served as
a control group. The transferred WT T cells readily differentiated
into IFNgexpressing cells both in the spleens (Figures 2F, 2G,
and 2H) and the tumors (Figures 2F and 2I) of miR-155/
mice. This significantly increased the percentage of IFNg-ex-
pressing cells within the tumors, but did not reachWT levels (Fig-
ure 2J). Furthermore, tumors in miR-155/ mice having
received WT CD4+ T cells trended toward being smaller than
tumors growing in miR-155/ mice that received miR-155/Cell ReCD4+ T cells (Figure 2K). Cellular engraftment and IFNg+CD4+
T cell differentiation (by the transferred WT T cells) was more
robust in miR-155/ versus WT recipients (Figures 2F, 2G,
and 2H), possibly due to an increased availability of T cell
niches in mice lacking miR-155. These findings, and similar
observations with EL4-luc tumor cells (Figure S3), indicate that
miR-155 plays a cell-intrinsic role during the formation of IFNg-
expressing CD4+ T cells in response to solid tumor growth.
miR-155 Is Required for Accumulation of IFNg+CD8+
T Cells in Tumors, and This Also Occurs through a CD8+
T Cell-Intrinsic Mechanism
The immune response against solid tumors involves multiple cell
types, including both CD4+ and CD8+ T cells. Although we have
found a clear T cell-intrinsic function for miR-155 in the promo-
tion of IFNg responses by CD4+ T cells in response to solid
tumors, a role formiR-155 in CD8+ T cell biology during antitumor
immunity has not been reported. Thus, we first examined IFNg
expression by CD8+ T cells following their activation in vitro,
and observed defective IFNg mRNA levels in the absence of
miR-155 (Figure 3A). Next, we assessed the CD8+ TIL population
in tumors growing in WT versusmiR-155/mice, and observed
a reduction in the percentage of IFNg+CD8+ T cells among
total CD8+ T cells in the absence of miR-155 (Figure 3B).
Adoptively transferred miR-155/ CD45.2+ CD8+ T cells were
significantly defective in accumulating and producing IFNg in
tumors growing in CD45.1+ WT mice, indicating a cell-intrinsic
role for miR-155 in CD8+ T cells (Figure 3C). Further supporting
a CD8+ T cell-intrinsic role for miR-155, transfer of WT
CD45.1+CD8+ T cells into sublethally irradiated CD45.2+ WT or
miR-155/ hosts followed by a tumor challenge revealed that
WT CD8+ T cells could still mediate strong IFNg responses in
a miR-155/ environment (Figures 3D and 3E). miR-155/
mice receiving WT CD8+ T cells also tended to have reduced
tumor weights compared with those receiving miR-155/
CD8+ T cells (Figure 3E). Thus, miR-155 functions within both
CD4+ and CD8+ T cells to promote IFNg-dependent antitumor
immunity.
miR-155 Plays a Dominant Role Compared to miR-146a
during T Cell-Mediated Tumor Immunity
Like miR-155, miR-146a is also expressed in activated T cells.
However, in contrast to miR-155, miR-146a/ T cells have
been reported to be hyperactivated during acute and chronic
immune responses (Yang et al., 2012). Therefore, we tested
whether miR-146a/ mice have enhanced antitumor immunity
compared to WT mice. miR-146a/, miR-155/, and WT
mice were inoculated subcutaneously with 1 3 106 B16-F10
cells and tumor growth was monitored over a time course (Fig-
ure 4A). Interestingly, tumors grew at a reduced rate in the
absence of miR-146a compared to WT mice, while once again
they grew larger inmiR-155/mice, suggesting that these miR-
NAs play opposing roles during antitumor responses.
To examine the cross-regulation of tumor immunity by miR-
155 and miR-146a, we created mice deficient in both miRNAs
(Figure 4B). Using these mice, we assessed whether these
opposing phenotypes would be canceled out, or if one of these
two miRNAs plays a dominant role. DKO mice were viable andports 2, 1697–1709, December 27, 2012 ª2012 The Authors 1699
Figure 2. miR-155 Promotes IFNg+CD4+ T Cell Formation in Tumor-Bearing Mice through a CD4+ T Cell-Intrinsic Mechanism
(A) IFNg expression by CD4+ T cells from the spleens of EL4-luc tumor-bearing WT or miR-155/ mice following 12 days of tumor growth.
(B) Results from (A) are shown graphically for multiple mice (n = 5).
(C) Number of IFNg+CD4+ T cells in the spleens of WT or miR-155/ mice with and without B16-F10 tumors for 14 days.
(D) FACS plots (gated on CD4+ T cells) showing IFNg expression by transferred WT ormiR-155/ CD45.2+ CD4+ T cells in the tumors of WT CD45.1+ B16-F10
tumor-bearing mice.
(E) Graphs from multiple mice in (D) (n = 5).
(F) FACS plots showing IFNg expression by transferred WT CD45.1+ CD4+ T cells in the spleens (top) or tumors (bottom) of WT ormiR-155/ CD45.2+ B16-F10
tumor bearing mice. Transferred miR-155/ CD4+ cells are CD45.2+ and all plots are gated on CD4+ T cells.
(legend continued on next page)
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fertile and did not exhibit obvious gross abnormalities by the age
of 8 weeks. The absence of both miR-155 andmiR-146a expres-
sion was confirmed by quantitative PCR (qPCR) using RNA from
in vitro activated CD4+ T cells (Figure 4C). When these mice and
the relevant control groups were challenged with 1 3 106 B16-
F10 tumor cells, there was a consistent trend toward increased
tumor growth in DKO compared to WT mice, similar to tumors
growing in miR-155/ mice (Figures 4D and 4E). Again, miR-
146a/ mice restricted tumor growth compared to WT mice.
IFNg+CD4+ T cell numbers in the spleens of both DKO and
miR-155/ tumor-bearing mice were significantly reduced
compared to WT mice, while miR-146a/ mice had the highest
levels (Figure 4F). This same trend was also observed when
CD45.2+ WT, miR-155/, miR-146a/, or DKO CD4+ T cells
were transferred into CD45.1+ WT mice followed by 15 days of
tumor growth, consistent with these miRNAs playing CD4+
T cell intrinsic roles to regulate IFNg production (Figures 4G
and 4H).
Upon analyzing single cell tumor suspensions by fluores-
cence-activated cell sorting (FACS), miR-155/ and DKO
mice had reduced percentages of cells in the forward scatter-
side scatter leukocyte gate versus those observed in WT mice,
and this cellular compartment contained CD3+CD4+ and CD3+
CD8+ TILs (Figure 5A). Alternatively, increased percentages of
TILs were observed in tumors from miR-146a/ compared to
WT mice (Figure 5A). The percentages of IFNg+CD4+ and
IFNg+CD8+ T cells among total CD4+ or CD8+ TILs, respectively,
were reduced in tumors growing in miR-155/ and DKO mice,
and marginally increased in tumors from miR-146a/ animals
(Figures 5B and 5C). Upon FACS sorting CD3+CD4+ or
CD3+CD8+ TILs from the tumors, we recovered fewer numbers
of total and IFNg+CD4+ and IFNg+CD8+ T cells from tumors
growing in miR-155/ and DKO mice compared to WT mice,
while miR-146a/ mice had elevated amounts (Figures 5D
and 5E). Furthermore, miR-155 and miR-146a were expressed
in both CD4+ and CD8+ TILs (Figure S4). Together, these obser-
vations indicate that miR-155 plays dominant, T cell-intrinsic
roles in promoting antitumor responses by both CD4+ and
CD8+ T cells.
miR-155 Targets the IFNg Regulator Ship1 in T Cells
Because we found that miR-155 functions in CD4+ T cells during
the antitumor response, we FACS sorted CD4+ T cells from the
spleens of miR-155/ and WT tumor-bearing mice and
analyzed gene expression differences to obtain mechanistic
insight into its impact on IFNg expression. Derepression of
Ship1, a previously identified target of miR-155 in myeloid cells
(O’Connell et al., 2009), was observed by qPCR in cells lacking
miR-155 (Figure 6A). BIC, the noncoding RNA that produces(G) Graph showing IFNg expression by the splenic CD4+ T cell compartment in B
(H) Total number of engrafting CD45.1+ WT CD4+ T cells in WT versus miR-155
(I) Graph showing the percentage of IFNg+CD4+ T cells among total CD4+ T cells in
(J) The amount of IFNg-expressing CD45+ cells among total CD45+ cells in t
genotypes (n = 5–7).
(K) Tumor weights from (J).
* denotes a p value less than 0.05. Data are presented as ± SEM. Tu, tumor; Sp
See also Figures S2 and S3.
Cell RemiR-155, was assayed as a control and not detected in miR-
155/ cells. To assay Ship1 expression at the protein level in
miR-155/ CD4+ T cells, western blotting was performed using
lysates prepared from naive WT or miR-155/ T cells that had
been activated with aCD3 and aCD28 antibodies for 96 hr (Fig-
ure 6B). Elevated Ship1 protein concentrations were observed
inmiR-155/ T cells under these conditions. Next, we extended
our analysis to activated DKO CD4+ T cells and again found
enhanced expression of Ship1 at the protein and mRNA levels
in both miR-155/ and DKO CD4+ T cells compared to WT
and miR-146a/ cells (Figures 6C and 6D). Importantly, levels
of Ship1 inversely correlated with the expression of IFNg in
WT, miR-155/, and DKO T cells (Figure 6E). Of note, there
was little impact by the different miRNA deficiencies on CD4+
T cell growth in vitro (Figure S5), and activated miR-146a/
CD4+ T cells still produced elevated levels of IFNg even after
CD25+ T regulatory cells were depleted (Figure S6).
To test the functional impact of elevated Ship1 expression (as
observed in the absence of miR-155) on IFNg levels, we utilized
small hairpin RNAs (shRNAs) to knock down Ship1 expression in
activated WT, miR-155/, miR-146a/, or DKO CD4+ T cells.
We found that in T cells of all genotypes tested, reductions in
Ship1 using either of two different shRNAs resulted in increased
expression of IFNg mRNA compared to cells given a scrambled
control vector (Figure 6F). Knockdown by the shRNA was
confirmed by western blotting against Ship1 (Figure 6G). Expres-
sion of a Ship1 shRNA in activated CD4+ T cells also increased
production of IFNg at the protein level as determined by ELISA
(Figure 6H). Retroviral transduction of CD4+ T cells was approx-
imately 50% in all cases as determined by FACS to identify GFP+
cells. Next, we also assayed Ship1 protein levels in CD8+ T cells
from the different groups. Like CD4+ T cells, Ship1 was also
elevated in miR-155/ and DKO compared to WT and miR-
146a/ CD8+ T cells (Figure 6I). Taken together, these findings
indicate that Ship1 is repressed by miR-155 in both CD4+ and
CD8+ T cells. Furthermore, miR-155 promotes IFNg expression
by CD4+ T cells through a mechanism involving repression of
Ship1. However, the partial recovery of the IFNg phenotype
following Ship1 knockdown indicates that addition targets of
miR-155 are also involved in this phenotype.
DISCUSSION
MicroRNA-155 has quickly emerged as an important promoter of
inflammatory responses, with a clear connection to autoimmu-
nity. Furthermore, miR-155 is overexpressed in a variety of tumor
cell types and can promote tumor growth in many cases (Bakirtzi
et al., 2011; Chang et al., 2011; Han et al., 2012; Philippidou
et al., 2010; Segura et al., 2010; Volinia et al., 2006; Zheng16-F10 tumor-bearing miR-155/ mice receiving WT CD4+ T cells (n = 5–7).
/ tumor-bearing mouse spleens.
the tumor. Contribution by transferred versus endogenous cells is also shown.
he B16-F10 tumors is shown graphically for multiple mice of the indicated
, spleen.
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Figure 3. miR-155 Promotes IFNg+CD8+ T
Cell Responses In Tumor-Bearing Mice
through a CD8+ T Cell-Intrinsic Mechanism
(A) Expression levels of IFNg in aCD3 and aCD28
activated CD8+ splenic T cells from WT or miR-
155/ mice were assayed by qPCR.
(B) The percentage of IFNg+CD8+ TILs among total
CD8+ TILs from tumors growing in WT or miR-
155/ mice (n = 5).
(C) FACS plots of B16-F10 tumor cell suspensions
looking at IFNg expression by the transferred WT
and miR-155/ CD45.2+ CD8+ T cells in CD45.1
WT tumor-bearing hosts (n = 5). Plots are gated on
CD8+ T cells.
(D) FACS plots of B16-F10 tumor cell suspensions
looking at IFNg expression by the transferred WT
CD45.1+ CD8+ T cells in WT or miR-155/
CD45.2+ tumor hosts. Plots are gated on CD8+
T cells.
(E) The percentage of CD45.2+ endogenous CD8+
TILs versus transferred WT CD45.1+ CD8+ TILs
expressing IFNg among total CD8+ T cells is
shown graphically for multiple mice of the indi-
cated genotypes (n = 5–7).
(F) Tumor weights from (D) are shown.
* denotes a p value less than 0.05. Data are pre-
sented as ± SEM.et al., 2012). Thus, it has been suggested that therapeutic inhibi-
tion of miR-155 may be a strategic means to treat autoimmunity
or cancer. However, in the current study, we found that trans-
ferred syngeneic tumors grew substantially larger in mice genet-
ically deficient in miR-155. Despite the tumors being weakly
immunogenic, defects in the antitumor immune response were
observed in the absence of miR-155, demonstrating a protective
role for this miRNA in immune cells in the context of a tumor chal-1702 Cell Reports 2, 1697–1709, December 27, 2012 ª2012 The Authorslenge. Consequently, clinical approaches
aimed at targeting miR-155 within tumor
cells themselves could have deleterious
consequences if unintended repression
of miR-155 occurs in immune cells. One
could imagine this to be highly possible
because solid tumors are physically
associated with TILs. Furthermore, inhibi-
tion of miR-155 to treat autoimmunity
might also block protective functions
mediated by miR-155, including tumor
immunosurveillance. Thus, our results
clearly indicate the need for highly
specific and targeted approaches to
modulating miR-155 levels in the treat-
ment of human disease.
There has been much consideration for
using miR-155 as a biomarker of disease
type and severity in human cancers
where it is commonly overexpressed.
Several instances of increased miR-155
levels correlating with more aggressive
tumors with poor clinical outcomes havebeen reported (Chang et al., 2011; Han et al., 2012). However,
a recent study looking at human melanoma patients found that
increased miR-155 expression correlated with an improved
prognosis (Segura et al., 2010). Although the study did not
analyze distinct cellular subsets within the tumor, one could
speculate that the increased miR-155 expression was a conse-
quence of enhanced accumulation of immune cells within the
tumor. Based upon our results here, it may prove valuable to
Figure 4. Enhanced Tumor Growth and Defective Numbers of IFNg-Expressing CD4+ T Cells in miR-155/ miR-146a/ DKO Mice
(A) WT, miR-155/, and miR-146a/ mice were inoculated subcutaneously with 1 3 106 B16-F10 tumor cells and the tumor diameters were measured over a
15-day time course (n = 5).
(B) Genotyping results from PCR assays demonstrating the generation of miR-155 and miR146a DKO mice.
(C) Expression of miR-155 or miR-146a in activated CD4+ T cells from the indicated genotypes.
(D) B16-F10 tumor growth in WT, miR-155/, miR-146a/, and DKO mice (n = 10).
(E) Tumor weights following resection 15 days after injection with tumor cells (n = 15–24).
(F) Total number of IFNg+CD4+ T cells in the spleens of WT, miR-155/, miR-146a/, and DKO tumor-bearing mice (n = 5).
(G) CD45.2+ WT,miR-155/,miR-146a/, or DKO naive CD4+ T cells were injected into sublethally irradiated CD45.1+ WT mice 1 day before being inoculated
with 5 3 105 B16-F10 cells. IFNg expression by the transferred CD4+ T cells in the spleens of tumor-bearing mice was assayed 15 days later.
(H) Number of IFNg-expressing cells from (G) is shown (n = 5).
* denotes a p value less than 0.06. Data are presented as ± SEM.carefully assess whether overexpression of miR-155 is occurring
in tumor cells or in TILs that are actively fighting the tumor. This
may give a more accurate assessment of whether increases in
miR-155 are protective or deleterious.Cell ReWhereas miR-155 plays a host protective role against solid
tumor growth, miR-146a appears to limit immunity against the
same tumor type. We provide evidence that these contrasting
roles are the consequence of reciprocal effects by thesemiRNAsports 2, 1697–1709, December 27, 2012 ª2012 The Authors 1703
(legend continued on next page)
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on the tumor accumulation of IFNg expressing cells, including
CD4+ and CD8+ T lymphocytes, which are critical mediators of
antitumor immunity. These findings demonstrate that miRNAs
in the immune system can play opposing roles in the regulation
of a given phenotype. Thus, it is plausible that sets of miRNAs
have evolved to provide balance to specific aspects of mamma-
lian immunity, as has been proposed in stem cells (Melton et al.,
2010). Consequently, we tested whether miR-155 and miR-146a
function to provide immunological balance, or if one of these
miRNAs has a dominant effect on IFNg+ T cell formation and anti-
tumor immunity. Using DKO mice, we determined that loss of
miR-155 is largely epistatic to a deficiency in miR-146a in the
contexts of IFNg+ T cell formation and antitumor immunity. The
enhanced antitumor response observed in miR-146a/ mice
was not only dependent upon miR-155 but was also worse
than that observed in WT mice when miR-155 was also geneti-
cally absent. Therefore, our results indicate that miR-155 plays
a dominant role, compared to miR-146a, in this context.
Although studies carried out by our lab and others have
provided evidence that these miRNAs oppose one another
within T cells, it is probable that miR-155 and miR-146a impact
antitumor immune responses by also acting in non-T cell types,
such as macrophages, dendritic cells, and natural killer cells,
where they have been shown to be expressed and to impact
inflammatory responses (Boldin et al., 2011; Cubillos-Ruiz
et al., 2012; O’Connell et al., 2007; Trotta et al., 2012). Once
conditional knockout mice are available for miR-155 and miR-
146a, studies can be carried out to specifically test the relative
contributions of these miRNAs to the functions of distinct cell
types that drive tumor immunity, and this will shed additional
light on the cellular basis of the observed epistasis.
In an effort to unravel the molecular basis for miR-155’s func-
tion in the T cell compartment, we found the miR-155 target
Ship1 to be part of the connection between miR-155 and IFNg
expression by CD4+ T cells. Ship1 is a phosphatase that nega-
tively regulates cytokine signaling via repression of the PI3K
pathway (Kerr, 2011). A recent study looking at deletion of
Ship1 specifically in CD4+ T cells using a CD4-CREmouse strain
with floxed Ship1 alleles found that Ship1 expression in T cells
promotes IFNg expression by CD4+ T cells (Tarasenko et al.,
2007). Consistent with these observations, our Ship1 shRNA
experiments found that defective expression of IFNg by miR-
155/ CD4+ T cells could be partially complemented by
reducing levels of Ship1, which are elevated in these cells. The
same observations were made in DKO CD4+ T cells, indicating
that Ship1 plays an increased inhibitory role when miR-155 is
absent from either WT or normally hyperactive miR-146a/
T cells. This effect of Ship1 provides at least part of the explana-
tion for why miR-155 is dominant in the CD4+ T cell compart-
ment. However, miR-155 is known to repress a variety ofFigure 5. Dominant Role for miR-155 versus miR-146a during T Cell-M
(A) Representative FACS plots showing the percentage of tumor infiltrating C
mice (n = 5).
(B–E) Representative FACS plot demonstrating expression of IFNg by (B) CD4+ an
tumor) of IFNg+ and IFNgCD3+CD4+ (D) or CD3+CD8+ (E) TILs sorted from tumor
experiments. Data are presented as ± SEM.
See also Figure S4.
Cell Redifferent mRNA targets, such as cMaf, PI3K p85, and Socs1,
which could also influence IFNg responses by T cells. These
proteins, in addition to Ship1, can act as inhibitors of IFNg or
cellular activation in general (Huang et al., 2012; Lu et al.,
2009; Rodriguez et al., 2007). Therefore, it is likely that miR-
155 repression of this group of targets underlies its function in
CD4+ T cells. In the case of CD8+ T cells, we also observed
increased Ship1 expression in the absence of miR-155. Ship1
has been shown to inhibit CD8+ T cell cytotoxicity (Tarasenko
et al., 2007), suggesting that its regulation by miR-155 is also
relevant in this cellular compartment. However, like CD4+
T cells, additional targets of miR-155 are also likely involved.
There is increasing evidence that the crosstalk between the
pathways regulated bymiR-155 andmiR-146a in T cells involves
regulators of NF-kB activity, a transcription factor involved in
IFNg transcription. miR-146a/ T cells have just been shown
to have increased activation of NF-kB following T cell receptor
engagement as a result of derepression of its targets IRAK1
and TRAF6 (Yang et al., 2012). This causes increased expression
of IFNg by effector T cells deficient in miR-146a. Consequently, it
is possible that the elevated levels of Ship1 (Figure 5) and Socs1
(Lu et al., 2009) that are observed in miR-155/ T cells act to
inhibit NF-kB activation, as they have been shown to do in other
cell types (Gabhann et al., 2010; Serezani et al., 2011; Strebov-
sky et al., 2011). This would negate the enhanced T cell activa-
tion observed in the absence of miR-146a alone. A careful
dissection of these signaling pathways in the context of the
different miRNA deficiencies will be an important future
endeavor.
Taken together, our study identifies a protective role for miR-
155, and an inhibitory function for miR-146a, during antitumor
immune responses, and argues for the importance of developing
highly specific methods of modulating miRNAs when such
approaches are used to combat cancer or autoimmunity. Addi-
tionally, by combining approaches that enhance miR-155 and/
or repressmiR-146a levels in T lymphocyteswith tumor vaccines
or adoptive cell transfer therapies, one might achieve increased
therapeutic efficacy in the clinic. Further studies will also be
necessary to determine if miR-155 or miR-146a impact tumor
metastasis in addition to modulating tumor growth. Finally, the
importance of miR-155 in regulating IFNg+ T cell responses
during tumor immunity is highlighted by the finding that a miR-
155 deficiency is epistatic to a loss of miR-146a in this cellular
compartment.EXPERIMENTAL PROCEDURES
Mice
All mice were on a C57BL6 genetic background and housed in the animal
facility at the University of Utah. Experiments were approved by theediated Antitumor Immune Responses
D3+CD4+ and CD3+CD8+ TILs in WT, miR-155/, miR-146a/, and DKO
d (C) CD8+ TILs from the indicated genotypes (n = 5). The number (per gram of
s growing in the different genotypes is shown. Data represent two independent
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Figure 6. Ship1 Is a Target of miR-155 in T Lymphocytes
(A) Expression levels of Ship1 mRNA and BIC noncoding RNA were determined in CD4+ T cells purified from the spleens of tumor bearing mice WT and miR-
155/ mice (n = 4).
(B) Expression of Ship1 was quantified in activated WT and miR-155/ CD4+ T cells by western blotting. Data from two WT and two miR-155/ mouse T cell
donors are shown.
(C and D) Expression of Ship1 in aCD3 and aCD28 activated CD4+ splenic T cells from WT,miR-155/,miR-146a/, and DKO mice was assayed by western
blotting and qPCR.
(E) Expression of IFNg mRNA in the same cells from (D) is shown (n = 2).
(F) aCD3 and aCD28 antibody activated CD4+ splenic T cells from WT, miR-155/,miR-146a/, and DKO mice were transduced with a control or one of two
different Ship1 shRNA producing retroviral vectors after 24 hr of activation. Expression of Ship1 and IFNg mRNA levels were assayed by qPCR after 72 hr of
knockdown. Data are presented as the ratio of expression in the shRNA versus control (scrambled) conditions. The average knockdown of Ship1 or increase in
IFNg for all genotypes is shown on the right.
(G) Knockdown of Ship1 in the different cell types by the Ship1 shRNA was determined by western blotting.
(legend continued on next page)
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Institutional Animal Care and Use Committee at the University of Utah and
used mice 6–12 weeks of age. miR-155/ were crossed with miR-146a/
to create miR-155/miR146a/ (DKO) mice. Genotyping was performed
as described (Boldin et al., 2011; Rodriguez et al., 2007). Xenogen live animal
imaging to observe tumor expression of luciferase was performed as
described (O’Connell et al., 2010a). Irradiation was delivered using an X-ray
source.
Tumor Challenges and Harvests
To create syngeneic subcutaneous tumors in mice, either EL4-luc lymphoma,
B16-F10 melanoma, or B16-F1 melanoma cells were injected into the rear
flanks of mice. The sites of tumor cell administration were shaved and cleaned
before injection. Tumor growth was monitored over a time course by
measuring tumor diameter. For analyses at the end of the time course, mice
were euthanized and their tumors, spleens, and lymph nodes were removed
and processed for FACS or histology. Following dissection, the tumors were
weighed, minced into small pieces using a razor blade, and subsequently
digested using Accumax. After the enzymatic digestion, the tumor cells
were washed before further analysis. In some experiments, TILs were purified
using FACS.
Adoptive Transfer of CD4+ and CD8+ T Cells
For T cell transfer experiments, CD4+ or CD8+ T cells were purified from
naive mice (see below) and the indicated amounts of T cells were injected
intravenously into recipient mice 1 day before tumor administration. In
some experiments, recipients were first irradiated with 500 Rads using an
X-ray source before receiving T cells. To distinguish between donor and
recipient T cells, CD45.1 and CD45.2 congenic mouse strains were used
when possible.
T Cell Isolation and Retroviral Infections
T cells were purified from red blood cell-lysed splenocytes using the
MACS CD4+ or CD8+ T cell isolation kit (negative selection) from Miltenyi.
Purity was assessed by FACS and routinely reached 90%–95%. To create
replication-deficient murine stem cell virus-based retroviral particles
carrying the Ship1 or a scrambled control shRNA sequence, 293T cells
were transfected with the MGP backbone and pCL-Eco packaging plas-
mids and retrovector-containing supernatant was recovered after 48 hr.
The shRNA Ship1 expression vector has been described previously
(O’Connell et al., 2009). For retroviral transduction of CD4+ T cells, the
cells were stimulated with aCD3 (3 mg/ml) and aCD28 (2 mg/ml) for 24 hr,
subjected to a spin infection using retrovirus medium at 2,500 rpm at
30C for 1.5 hr, then brought up in fresh activation medium for another
72 hr. Cellular infection was determined by microscopy or FACS to iden-
tify GFP+ cells.
Intracellular Staining and FACS
Intracellular staining was performed as described previously (O’Connell
et al., 2010b). In short, 1 3 106 splenocytes, lymph node cells, or tumor
suspension cells were restimulated with phorbol myristate acetate and
ionomycin for 4 hr in the presence of Golgi Plug. Cells were next surface
stained with aCD4 or aCD8 antibodies, washed, and permeabilized over-
night using Perm Fix. After washing with Perm Buffer, the cells were
stained using a phycoerythrin-conjugated mouse IFNg antibody. Following
washing, cells were analyzed by FACS using a BD LSR Fortessa. For
FACS sorting, cells were surface stained with aCD45 (pan), aCD3, and
aCD4 or aCD8 fluorophore-conjugated antibodies, and cellular popula-
tions were sorted using a FACS Aria II in the Flow Cytometry Core Facility
at the University of Utah. Other antibodies used for FACS include aCD45.1
and aCD45.2.(H) Retroviral transduction of shRNAs against Ship1 into CD4+ T cells from the in
supernatants were determined by ELISA 72 hr after T cell activation.
(I) Ship1 expression levels were determined by western blotting in aCD3 and aC
IFNg for all genotypes is shown on the right.
* denotes a p value less than 0.05. Data are presented as ±SEM. See also Figur
Cell ReWestern Blotting, ELISA, and qPCR
Western blotting using cellular extracts from T lymphocytes was performed
using standard protocols. Antibodies against mouse Ship1 and b-actin were
obtained from Santa Cruz Biotechnology. For qPCR, RNAwas extracted using
the RNeasy or miRNeasy kits from QIAGEN per manufacturer’s instructions.
Following cDNA synthesis using total RNA, SYBRgreen-based qPCR was
performed with gene-specific primers and the Roche Light Cycler 480. Primer
sequences are available upon request. For detection of mature miRNAs
155 and 146a, or 5S ribosomal RNA, reagents and protocols from Exiqon
were utilized. The ELISA assay used to quantify mouse IFNg concentrations
was obtained from eBioscience and performed using the manufacturer’s
suggested protocol.
Histopathology
The tumors were dissected from the respective hosts and fixed with 10%
formalin for at least 48 hr at room temperature. After fixation, the tumors
were bisected across a maximum dimension and processed for paraffin
embedding. Next, 5 mm-thick tissue sections were cut from paraffin blocks
and stained with H&E per standard H&E protocol. The histopathological
analysis was performed by a board-certified pathologist, and the images
were taken using an Olympus BX41/DP72 microscope/camera. The magnifi-
cation of the objective lens for each image is provided in the figures.
Statistical Analysis
A Student’s t test was performed to determine statistical significance.
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Supplemental Information
Figure S1. Quantification of Tumor Imaging Data, Related to Figure 1
Luminescent signals from EL4-luc tumors growing in WT or miR-155/mice are quantified using Xenogen living image software. * denotes a p value less than
0.05. Data are presented as ±SEM.
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Figure S2. Percentage and Number of IFNg+CD4+ T Cells in the Lymph Nodes of EL4 Tumor-Bearing WT and miR-155/ Mice, Related to
Figure 2
(A) IFNg expression by CD4+ T cells from the lymph nodes (LNs) of EL4-luc tumor bearing WT or miR-155/ mice following 12 days of tumor growth.
(B) Results are shown graphically for multiple mice (n = 5) on the right. * denotes a p value less than 0.05. Data are presented as ±SEM.
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Figure S3. Tumor EducatedmiR-155/Splenocytes Fail to Protect NaiveMice fromaTumorChallenge, andAdoptive Transfer ofWTCD4+ T
Cells into miR-155/ Mice Restores IFNg Expression by CD4+ T Cells in the Spleens of EL4-luc Tumor Bearing Mice, Related to Figure 2
(A) WT ormiR-155/mice were subcutaneously challenged with EL4-luc tumor cells for 14 days. Splenocytes were recovered from these two groups and 253
106 of these cells were injected i.v. into naive WT recipient mice who were subsequently inoculated with EL4-luc tumor cells. A control group not receiving
splenocytes was also given tumor cells.
(B and C) Tumor diameters over the 11-day timecourse (B) and final tumor weights (C) are shown graphically.
(D and E) Purified WT CD4+ CD45.1+ cells used for transfer (D) and representative FACS plots showing the adoptively transferred WT CD45.1+CD4+ T cells
expressing IFNg in the spleens of WT and miR-155/ EL4-luc tumor bearing mice (E) are shown.
(F) Expression of IFNg in the splenic CD4+ T cell compartment in EL4-luc tumor bearing mice receivingWTCD4+ T cells is shown on the right (n = 5). * denotes a p
value less than 0.05. Data are presented as ±SEM.
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Figure S4. miR-155 and miR-146a Are Expressed in CD4+ and CD8+ TILs, Related to Figure 5
Expression of miR-155 and miR-146a in sorted CD4+ and CD8+ TILs from WT or the indicated miRNA knockout mice was determined using qPCR.
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Figure S5. Proliferation of Activated WT, miR-155/, miR-146a/, or DKO CD4+ T Cells, Related to Figure 6
WT,miR-155/,miR-146a/, and DKO CD4+ T cells were stimulated with aCD3 and aCD28 and their cell numbers were determined daily for 96 hr (n = 2). Data
are presented as ±SEM.
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Figure S6. miR-146a/ CD25-Depleted CD4+ T Cells Express Higher Levels of IFNg Compared to WT CD4+ T Cells Following Their Acti-
vation In Vitro in Figure 6
(A) FACS plots showing sorted CD25-CD4+ T cells from WT or miR-146a/ mice.
(B) qPCR and ELISA was performed to assay IFNg expression in the sorted cell populations. Data are presented as ±SEM.
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